Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Large Decrease in Short Interest

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 73,800 shares, a decrease of 33.9% from the December 15th total of 111,600 shares. Based on an average daily volume of 119,800 shares, the short-interest ratio is presently 0.6 days. Approximately 0.5% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Sphera Funds Management LTD. purchased a new position in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned 8.46% of Chemomab Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Stock Performance

Shares of Chemomab Therapeutics stock opened at $1.90 on Wednesday. The stock has a market capitalization of $27.28 million, a P/E ratio of -1.90 and a beta of 0.65. Chemomab Therapeutics has a 52-week low of $0.46 and a 52-week high of $2.55. The stock’s 50-day simple moving average is $1.78 and its 200 day simple moving average is $1.54.

Analyst Ratings Changes

Separately, Oppenheimer restated an “outperform” rating and issued a $11.00 target price (down previously from $13.00) on shares of Chemomab Therapeutics in a research note on Friday, November 15th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).